The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 19, 2016

Filed:

Feb. 23, 2012
Applicants:

Ben K. Seon, Williamsville, NY (US);

Hirofumi Toi, Hokkaido, JP;

Inventors:

Ben K. Seon, Williamsville, NY (US);

Hirofumi Toi, Hokkaido, JP;

Assignee:

Health Research, Inc., Buffalo, NY (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01); C07K 16/18 (2006.01); A61K 39/395 (2006.01); C07K 16/30 (2006.01); C07K 16/28 (2006.01); A01K 67/027 (2006.01); C07K 14/705 (2006.01); C12N 15/85 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/30 (2013.01); A01K 67/0278 (2013.01); C07K 14/70596 (2013.01); C07K 16/2896 (2013.01); C12N 15/85 (2013.01); A01K 2207/15 (2013.01); A01K 2217/072 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0375 (2013.01); A61K 2039/505 (2013.01);
Abstract

Provided are compositions and methods that relate to prophylaxis and therapy of angiogenesis associated disease and includes novel knockin mice which express novel human/mouse chimeric endoglin, vectors for use in making such mice, and murine embryonic stem cells comprising the novel human/mouse transgene. Also provided are anti-human endoglin monoclonal antibodies (mAbs) which can be used as antiangiogenic agents for prophylaxis or therapy of human tumor angiogenesis and human angiogenesis-associated diseases having excessive vascularization. The mAbs do not cross react with murine endoglin. Also provides are methods for using the anti-human endoglin mAbs for prophylaxis or therapy of human tumor angiogenesis and for angiogenesis-associated diseases having excessive vascularization.


Find Patent Forward Citations

Loading…